Crystallization of intact monoclonal antibodies

Published on Oct 1, 1995in Proteins2.501
· DOI :10.1002/prot.340230218
Lisa J. Harris3
Estimated H-index: 3
(UCR: University of California, Riverside),
Eileen Skaletsky3
Estimated H-index: 3
Alexander McPherson51
Estimated H-index: 51
(UCR: University of California, Riverside)
Attempts were made to crystallize four monoclonal antibodies, one IgG2ak and three IgG1k. Using a PEG 3350 screen combined with detergents, and developed from our experiments with an IgG2ak antibody specific for canine lymphoma cells,1,2 crystals have now been obtained of two of these four immunoglobulins, an antiphenytoin and an antiphenobarbital antibody. A complex between the antiphenobarbital antibody and its drug antigen crystallized as well. The antibody for phenytoin has, to this point, produced only clustered microcrystals, marginally suitable for X-ray analysis. Single crystals of the IgG1k antibody against phenobarbital, however, were characterized by X-ray diffraction to be primitive monoclinic, with unit cell dimensions a = 67 A, b = 193 A, c = 74 A, and β = 110°. These crystals have an entire IgG1k molecule as the asymmetric unit and they diffract to at least 3.2 A resolution. © 1995 Wiley-Liss, Inc.
  • References (17)
  • Citations (50)
📖 Papers frequently viewed together
315 Citations
312 Citations
16 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Eduardo A. Padlan (NIH: National Institutes of Health)H-Index: 34
Abstract The structures of the various regions of an antibody molecule are analysed and correlated with biological function. The structural features which relate to potential applications are detailed.
828 CitationsSource
#1Ian A. Wilson (Scripps Research Institute)H-Index: 136
#2J.B. Ghiara (Scripps Research Institute)H-Index: 6
Last. Robyn L. Stanfield (Scripps Research Institute)H-Index: 54
view all 3 authors...
25 CitationsSource
#1Allen B. EdmundsonH-Index: 35
#2Luke W. GuddatH-Index: 39
Last. B.L. HansonH-Index: 2
view all 5 authors...
Conformational changes in immunoglobulin fragments on complexation were first noted in trigonal crystals (ammonium sulphate form) of the Meg light chain dimer in 1974 (Edmundson et al., 1974). Additional studies with Meg crystals demonstrated how induced fit mechanisms increase the diversity of ligands which can be bound by a single active site (Ely et al., 1978; Edmundson el al., 1984, 1987, 1989, 1993; Edmundson and Ely, 1985). The ligandinduced conformational changes in the Meg dimer were all...
5 CitationsSource
#1Steven Sheriff (BMS: Bristol-Myers Squibb)H-Index: 28
Abstract The X-ray crystallographic structures of five antibody-protein antigen complexes are briefly described. The three-dimensional structure of the antibody-antigen interface is compared to the results obtained by two other techniques: analysis of mutant binding data and NMR hydrogen-deuterium exchange.
13 CitationsSource
#1A.B. EdmundsonH-Index: 3
#2Luke W. GuddatH-Index: 39
Last. Kim N. AndersenH-Index: 3
view all 3 authors...
Crystal structures of intact IgG immunoglobulins have provided new insight into the interrelations of the Fab arms responsible for antigen binding and the Fc region mediating effector functions such as complement fixation and receptor attachment. Human immunoglobulins lacking the "hinge" region critical for segmental flexibility between the Fabs and the Fc (e.g., Dob and Mcg IgG1 proteins) exhibit Fc units that are represented by interpretable modules of electron density. In contrast, two human ...
12 CitationsSource
#1Lisa J. Harris (UCR: University of California, Riverside)H-Index: 3
#2Steven B. Larson (UCR: University of California, Riverside)H-Index: 16
Last. Alexander McPherson (UCR: University of California, Riverside)H-Index: 51
view all 6 authors...
CRYSTAL structures of Fab antibody fragments determined by X-ray diffraction characteristically feature four-domain, β-barrel arrangements1–3. A human antibody Fc fragment has also been found to have four β-barrel domains4. The structures of a few intact antibodies have been solved5–8: in two myeloma proteins, the flexible hinge regions that connect the Fc to the Fab segments were deleted5,6 so the molecules were non-functional, structurally restrained, T-shaped antibodies; a third antibody, Kol...
175 CitationsSource
#1Steven B. Larson (UCR: University of California, Riverside)H-Index: 16
#2John W. Day (UCR: University of California, Riverside)H-Index: 47
Last. Alexander McPherson (UCR: University of California, Riverside)H-Index: 51
view all 5 authors...
A monoclonal antibody of the subclass IgG2a specific for canine lymphoma cells has been crystallized by vapor diffusion from polyethylene glycol 8000. The crystals, which occasionally measure nearly a millimeter on edge, have been examined by X-ray diffraction. The crystals are of triclinic space group P1 with unit cell parameters of a = 66·39 A, b = 77·34 A, c = 101·42 A, α = 87·60 °, β = 92·55 °, γ = 97·54 ° and cell volume of V = 4·84 × 105A3. There is one entire antibody molecule as the asym...
16 CitationsSource
#1I. Saira Mian (Scripps Health)H-Index: 29
#2Arthur R. Bradwell (University of Birmingham)H-Index: 51
Last. Arthur J. Olson (Scripps Health)H-Index: 55
view all 3 authors...
Abstract Do antibody combining sites possess general properties that enable them to bind different antigens with varying affinities and to bind novel antigens? Here, we address this question by examining the physical and chemical characteristics most favourable for residues involved in antigen accommodation and binding. Amphipathic amino acids could readily tolerate the change of environment from hydrophilic to hydrophobic that occurs upon antibody-antigen complex formation. Residues that are la...
362 CitationsSource
#1Alexander McPherson (UCR: University of California, Riverside)H-Index: 51
Given our current expertise, and the certain future developments in genetically altering organisms to produce proteins of modified structure and function, the concept of protein engineering is nearing reality. Similarly, our ability to describe and utilize protein structure and to define interactions with ligands has made possible the rational design of new drugs and pharmacological agents. Even in the absence of any intention toward applied use or value, the correlation of regulation, mechanism...
401 CitationsSource
#1Pedro M. Alzari (Pasteur Institute)H-Index: 56
#2M B LascombeH-Index: 1
Last. R J Poljak (Pasteur Institute)H-Index: 1
view all 3 authors...
The first part of this article gives a summary of some of the most important results obtained by single-crystal X-ray diffraction techniques in the study of antibody structure. In the second part, recent result obtained in the authors’laboratory are discussed.
231 CitationsSource
Cited By50
Monoclonal antibodies (mAbs) are currently leading products in the global biopharmaceutical market. Multiple mAbs are in clinical development and novel biotherapeutic protein scaffolds, based on the canonical immunoglobulin G (IgG) fold, are emerging as treatment options for various medical conditions. However, fast approvals for biotherapeutics are challenging to achieve, because of difficult scientific development procedures and complex regulatory processes. Selecting molecular entities with s...
#1Elisabeth LobnerH-Index: 5
#2A. Humm (Max F. Perutz Laboratories)H-Index: 2
Last. Christian ObingerH-Index: 46
view all 8 authors...
ABSTRACTFcabs (Fc domain with antigen-binding sites) are promising novel therapeutics. By engineering of the C-terminal loops of the CH3 domains, 2 antigen binding sites can be inserted in close proximity. To elucidate the binding mode(s) between homodimeric Fcabs and small homodimeric antigens, the interaction between the Fcabs 448 and CT6 (having the AB, CD and EF loops and the C-termini engineered) with homodimeric VEGF was investigated. The crystal structures of these Fcabs, which form polym...
2 CitationsSource
#1Dariusch HekmatH-Index: 15
#2Max HuberH-Index: 1
Last. Dirk Weuster-BotzH-Index: 37
view all 5 authors...
A lab-scale stirred tank with a cooled tubular reactor in bypass was applied for continuous crystallization of lysozyme and a full-length therapeutic monoclonal antibody. The stirred tank was operated as a mixed suspension classified product removal crystallizer. Lysozyme was crystallized by a combination of cooling crystallization and salting-out. The antibody was crystallized by a combination of cooling crystallization and isoelectric crystallization. It was deduced that nucleation rates were ...
2 CitationsSource
#1Elisabeth LobnerH-Index: 5
#2A. Humm (Max F. Perutz Laboratories)H-Index: 2
Last. Christian ObingerH-Index: 46
view all 10 authors...
Summary The crystallizable fragment (Fc) of the immunoglobulin class G (IgG) is an attractive scaffold for the design of novel therapeutics. Upon engineering the C-terminal loops in the CH3 domains, Fcabs (Fc domain with antigen-binding sites) can be designed. We present the first crystal structures of Fcabs, i.e., of the HER2-binding clone H10-03-6 having the AB and EF loop engineered and the stabilized version STAB19 derived by directed evolution. Comparison with the crystal structure of the F...
5 CitationsSource
#1Nathan I. Nicely (Duke University)H-Index: 14
#2Kevin Wiehe (Duke University)H-Index: 23
Last. Barton F. Haynes (Duke University)H-Index: 124
view all 18 authors...
Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges w...
10 CitationsSource
#2S.J. HermansH-Index: 5
Last. Luke A. MilesH-Index: 15
view all 4 authors...
Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the first reported mid-region Aβ-anti-Aβ complex crystal structure. Solanezumab accommodates a large Aβ epitope (960 A2 buried interface over residues 16 to 26) that forms extensive contacts and hydrogen bond...
35 CitationsSource
#1Natalie Rakel (Hoffmann-La Roche)H-Index: 3
Last. Juergen HubbuchH-Index: 7
view all 4 authors...
Antibodies are complex macromolecules and their phase behavior as well as interactions within different solvents and precipitants are still not understood. To shed some light into the processes on a molecular dimension, the occurring self-interactions between antibody molecules were analyzed by means of the osmotic second virial coefficient (B22). The determined B22 follows qualitatively the phenomenological Hofmeister series describing the aggregation probability of antibodies for the various s...
11 CitationsSource
#1Dariusch Hekmat (TUM: Technische Universität München)H-Index: 15
Since about 170 years, salts were used to create supersaturated solutions and crystallize proteins. The dehydrating effect of salts as well as their kosmotropic or chaotropic character was revealed. Even the suitability of organic solvents for crystallization was already recognized. Interestingly, what was performed during the early times is still practiced today. A lot of effort was put into understanding the underlying physico-chemical interaction mechanisms leading to protein crystallization....
22 CitationsSource
#1Daniel Schweizer (Novartis)H-Index: 5
#2Tim Serno (Novartis)H-Index: 5
Last. Achim Goepferich (University of Regensburg)H-Index: 31
view all 3 authors...
The local administration of antibodies can represent in many cases a significant improvement for antibody-based therapies. The benefits of local delivery include high drug concentrations at the target site, the possibility of lower drug dosing and less systemic drug exposure. Currently, the most relevant delivery sites for therapeutic antibodies are the posterior segments of the eye, mucosal surfaces, the articular joints and the central nervous system (CNS). In addition, the oral and pulmonary ...
20 CitationsSource